She caught a lab issue early, tweaked my plan, and I never had to take time off work
CJC-1295/Ipamorelin is a self-injectable peptide that stimulates the release of growth hormone (GH), which is essential for muscle growth, metabolic function, and healing and recovery
Its just a little easier to fit into their busy life. How those hopes play out in reality now that the FDA has given its green light remains to be seen
Noticing these early and getting the right care makes a big difference
Some authors have reported extremely low or undetectable inhibin B levels alongside normal or subnormal Anti Mullerian Hormone (AMH) levels, indicating a specific defect in folliculogenesis
Topline Post-Bariatric AVEXITIDE data expected in Q3 2026, and if approved, commercial launch Hypoglycemia LUCIDITY PHASE 3 CLINICAL TRIAL anticipated in 2027 GLP-1 receptor (PBH) antagonist FDA-agreed upon primary outcome of reduction in the composite of Level 2 and Level 3 hypoglycemic events through Week 16 FDA Breakthrough Congenital Therapy and Orphan Engaging physician and community experts around next steps Hyperinsulinism Drug Designations for clinical development (HI) Pending alignment with the FDA, plan to initiate a focused, pivotal Phase 3 trial of AMX0035 in Wolfram syndrome AMX0035 Wolfram Positive Phase 2 HELIOS data showed improvement or stabilization HELIOS PHASE 2 CLINICAL TRIAL Sodium phenylbutyrate and Syndrome across all disease measures at Week 24 (N=11) and sustained taurursodiol (also known as improvement or stabilization at Week 48 (N=10) ursodoxicoltaurine) Early data from Cohort 1 (n=12) demonstrated AMX0114 was generally well-tolerated, with no treatment-related SAEs in Phase 1 AMX0114 Amyotrophic LUMINA trial ASO targeting calpain-2, a Lateral Sclerosis LUMINA PHASE 1 CLINICAL TRIAL protein involved in axonal Completed enrollment in Cohort 2 (n=12) in March 2026 (ALS) degeneration Granted FDA Fast Track designation As part of research collaboration with Gubra, AMX0318 demonstrated a robust chemical stability profile, strong in vitro potency, evidence of AMX0318 PBH and Other in vivo efficacy and tolerability, high solubility, and a favorable Long-acting GLP-1 Rare Diseases pharmacokinetic profile consistent with a long-acting peptide receptor antagonist IND-enabling studies underway, with an IND filing targeted for 2027 ASO=antisense oligonucleotide
